Jeff, I respectfully offer a counter. I testified in DOJ hearings back in 2005. In our market we found that CON on one side of the state line stifled innovation, and led to highly variant technologies on different sides of the state line. Genuinely improved technologies like PET-CT and IMRT were more available on one side of the state line than the other. Yet premiums across state lines were the same. We expected concern from the community regarding the value of these new technologies and measured those values and appropriate utilization so that we make sure we delivered on a value story for our community
Jeff, I respectfully offer a counter. I testified in DOJ hearings back in 2005. In our market we found that CON on one side of the state line stifled innovation, and led to highly variant technologies on different sides of the state line. Genuinely improved technologies like PET-CT and IMRT were more available on one side of the state line than the other. Yet premiums across state lines were the same. We expected concern from the community regarding the value of these new technologies and measured those values and appropriate utilization so that we make sure we delivered on a value story for our community